Progress on ocular siRNA gene-silencing therapy and drug delivery systems

被引：36

作者：

Jiang, Jinjin ^{[1
,2
]}

Zhang, Xinru ^{[1
,2
]}

Tang, Yue ^{[1
,2
]}

Li, Shuhan ^{[2
]}

Chen, Jing ^{[2
]}

机构：

[1] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, 1 DongQing Rd, Guiyang 550014, Peoples R China

[2] China Pharmaceut Univ, Dept Pharm, 639 Longmian Ave, Nanjing 211198, Peoples R China

来源：

FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2021年 / 35卷 / 01期

关键词：

age-related macular degeneration; glaucoma; RNA interference technology; siRNA drugs; non-viral vectors; ENDOTHELIAL GROWTH-FACTOR; BETA-ADRENERGIC RECEPTORS; VEGF SIRNA; POSTERIOR SEGMENT; POLYETHYLENIMINE NANOPARTICLES; INTRAVITREAL INJECTION; MACULAR DEGENERATION; NONVIRAL VECTORS; RNA INTERFERENCE; CLINICAL-TRIAL;

D O I：

10.1111/fcp.12561

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Age-related macular degeneration (AMD) and glaucoma are global ocular diseases with high blindness rate. RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF-04523655 for AMD, and SYL040012 and QPI-1007 for glaucoma. Administration routes and vectors of gene drugs affect their therapeutic effect. Compared with the non-viral vectors, viral vectors have limited payload capacity and potential immunogenicity. This review summarizes the progress of the ocular siRNA gene-silencing therapy by focusing on siRNA drugs for AMD and glaucoma already used in clinical research, the main routes of drug delivery and the non-viral vectors for siRNA drugs.

引用

页码：4 / 24

页数：21

共 50 条

[1] Novel delivery vehicle for ocular siRNA gene -silencing therapy
Monteiro, Amber
Liu, Lina
Sheardown, Heather
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
[2] Synthesis of guanidylated amphiphiles and bolaamphiphiles for siRNA encapsulation in gene-silencing therapy
Ynigez-Gutierrez, Audrey E.
Mfuh, Adelphe M.
Negrete, George R.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
[3] Gene-silencing drug approved
Ledford, Heidi
NATURE, 2018, 560 (7718) : 291 - 292
[4] Gene-silencing drug approved
Servick, Kelly
SCIENCE, 2018, 362 (6421) : 1349 - 1349
[5] Gene-silencing drug approved
Brainard, Jeffrey
SCIENCE, 2018, 361 (6403) : 629 - 629
[6] i-Motif-Driven Au Nanomachines in Programmed siRNA Delivery for Gene-Silencing and Photothermal Ablation
Son, Sejin
Nam, Jutaek
Kim, Jinhwan
Kim, Sungjee
Kim, Won Jong
ACS NANO, 2014, 8 (06) : 5574 - 5584
[7] Targeted delivery and enhanced gene-silencing activity of centrally modified folic acid-siRNA conjugates
Salim, Lidya
Islam, Golam
Desaulniers, Jean-Paul
NUCLEIC ACIDS RESEARCH, 2020, 48 (01) : 75 - 85
[8] Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart
Xiao, Chenglu
Wang, Fang
Hou, Junjie
Zhu, Xiaojun
Luo, Ying
Xiong, Jing-Wei
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2018, (137):
[9] Delivery systems for siRNA drug development in cancer therapy
Xu, Cong-fei
Wang, Jun
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 10 (01) : 1 - 12
[10] Direct delivery of gene-silencing molecules into brain by the olfactory route
Sanchez-Ramos, J.
Song, S.
Sava, V.
MOVEMENT DISORDERS, 2014, 29 (14) : 1845 - 1845

← 1 2 3 4 5 →